Cytori Therapeutics Inc  

(Public, NASDAQ:CYTX)   Watch this stock  
Find more results for CYTX
0.440
+0.010 (2.33%)
Jul 31 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.41 - 0.46
52 week 0.36 - 2.21
Open 0.44
Vol / Avg. 1.35M/1.85M
Mkt cap 66.40M
P/E     -
Div/yield     -
EPS -0.55
Shares 150.92M
Beta 2.99
Inst. own 20%
Aug 6, 2015
Q2 2015 Cytori Therapeutics Inc Earnings Call - 5:30PM EDT - Add to calendar
Aug 6, 2015
Q2 2015 Cytori Therapeutics Inc Earnings Release - 4:00PM EDT - Add to calendar
May 11, 2015
Q1 2015 Cytori Therapeutics Inc Earnings Call
May 11, 2015
Q1 2015 Cytori Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -935.98% -491.81%
Operating margin -895.01% -426.92%
EBITD margin - -423.95%
Return on average assets -232.49% -92.52%
Return on average equity - -
Employees 78 -
CDP Score - -

Address

3020 Callan Rd
SAN DIEGO, CA 92121-1109
United States - Map
+1-858-4580900 (Phone)
+1-858-4580994 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Cytori Therapeutics, Inc. (Cytori) is a biotechnology company involved in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company is engaged in developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns combined with radiation injury. The Company commercializes the Celution System under select medical device approvals, clearances and registrations to research customers developing new therapeutic applications for Cytori Cell Therapy in Europe, Japan and other regions. The Company offers ECCO-50, a cure for knee osteoarthritis, which is in ECCO-50 Phase IIA/B of development. It offers ECCI-50, a cure for urinary incontinence, which is in Phase II/III of development. The Company is also developing DCCT-10, a cure for cutaneous thermal injury.

Officers and directors

David M. Rickey Independent Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Marc H. Hedrick M.D. President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Tiago Girao Chief Financial Officer, Vice President - Finance
Age: 35
Bio & Compensation  - Reuters
Seijiro N. Shirahama President , Asia Pacific
Age: 60
Bio & Compensation  - Reuters
Steven Kesten Executive Vice President, Chief Medical Officer
Age: 56
Bio & Compensation  - Reuters
Jeremy Bragg Hayden Vice President - Business Development, General Counsel
Bio & Compensation  - Reuters
Richard J. Hawkins Independent Director
Age: 66
Bio & Compensation  - Reuters
Paul W. Hawran CPA Independent Director
Age: 63
Bio & Compensation  - Reuters
Gary A. Lyons Independent Director
Age: 64
Bio & Compensation  - Reuters
Gail K. Naughton Ph.D. Independent Director
Age: 59
Bio & Compensation  - Reuters